Short Interest in Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Increases By 94.9%

Key Points

• Short interest in Bayer rose 94.9% to 522,716 shares as of July 31, up from 268,144 shares two weeks earlier. Despite the increase, short interest represents approximately 0.0% of shares outstanding and 0.4 days of average trading volume.
• Analyst sentiment remains positive, with two Strong Buy ratings, five Buy ratings and one Hold rating. Recent upgrades from Deutsche Bank, Zacks Research and DZ Bank helped lift the stock’s consensus rating to “Buy.”
• Bayer reported quarterly EPS of $0.29, beating estimates of $0.23, while revenue reached $12.53 billion versus the $12.31 billion consensus. Shares were recently trading at $13.84, within a 52-week range of $7.48 to $15.23.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) was the target of a significant growth in short interest in July. As of July 31st, there was short interest totaling 522,716 shares, a growth of 94.9% from the July 15th total of 268,144 shares. Based on an average daily volume of 1,354,099 shares, the short-interest ratio is currently 0.4 days. Approximately 0.0% of the company's stock are sold short.

Wall Street Analysts Forecast Growth

BAYRY has been the topic of a number of recent research reports. Deutsche Bank Aktiengesellschaft raised Bayer Aktiengesellschaft from a "hold" rating to a "buy" rating in a research note on Thursday, July 2nd. Jefferies Financial Group raised shares of Bayer Aktiengesellschaft to a "hold" rating in a research report on Friday, May 29th. Zacks Research raised shares of Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a report on Friday, July 10th. Finally, DZ Bank upgraded shares of Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a report on Tuesday, May 19th. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, Bayer Aktiengesellschaft presently has an average rating of "Buy".

Bayer Aktiengesellschaft Stock Performance

Shares of BAYRY stock remained flat at $13.84 during trading hours on Friday. 396,144 shares of the stock were exchanged, compared to its average volume of 990,166. The company has a current ratio of 1.05, a quick ratio of 0.70 and a debt-to-equity ratio of 1.06. The business has a 50 day moving average of $13.03 and a two-hundred day moving average of $12.18. Bayer Aktiengesellschaft has a 52-week low of $7.48 and a 52-week high of $15.23. The firm has a market capitalization of $54.39 billion, a price-to-earnings ratio of -27.14, a PEG ratio of 4.34 and a beta of 0.55.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported $0.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.06. The company had revenue of $12.53 billion for the quarter, compared to analysts' expectations of $12.31 billion. Bayer Aktiengesellschaft had a negative net margin of 3.80% and a positive return on equity of 17.00%. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. Equities research analysts forecast that Bayer Aktiengesellschaft will post 1.28 EPS for the current year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women's health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source